中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.03 seconds)

    AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS
    1.
    发明申请
    AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS 审中-公开
    阿奇霉素剂型减少副作用

    公开(公告)号：WO2005053650A1

    公开(公告)日：2005-06-16

    申请号：PCT/IB2004/001654

    申请日：2004-05-14

    Applicant: PFIZER PRODUCTS INC. ,  HAGEN, Timothy, Arthur ,  HERBIG, Scott, Max ,  LO, Julian, Belknap ,  THOMBRE, Avinash, Govind ,  APPEL, Leah, Elizabeth ,  CREW, Marshall, David ,  FRIESEN, Dwayne, Thomas ,  LYON, David, Keith ,  MCCRAY, Scott, Baldwin ,  WEST, James, Blair

    Inventor： HAGEN, Timothy, Arthur ,  HERBIG, Scott, Max ,  LO, Julian, Belknap ,  THOMBRE, Avinash, Govind ,  APPEL, Leah, Elizabeth ,  CREW, Marshall, David ,  FRIESEN, Dwayne, Thomas ,  LYON, David, Keith ,  MCCRAY, Scott, Baldwin ,  WEST, James, Blair

    IPC: A61K9/16

    CPC classification number: A61K9/1611 ,  A61K9/143 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1694 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2031 ,  A61K31/7052

    Abstract: An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate,and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.

    Abstract translation: 口服剂型包含阿奇霉素和有效量的碱化剂。 优选地，所述口服剂型包含有效量的碱化剂和阿奇霉素多颗粒，其中所述多颗粒包含阿奇霉素，单山gly酸甘油酯，二山ate酸甘油酯和三山gly酸甘油酯的混合物以及泊洛沙姆。 典型地，口服剂型包括任何合适的口服给药方式，例如用于口服悬浮液的粉剂，单位剂量小包或小药囊，片剂或胶囊。另外公开的是口服悬浮液，其包含阿奇霉素，有效量的碱化剂和 一辆车。 优选地，阿奇霉素为多颗粒形式，其中所述多颗粒包含阿奇霉素，单山gly酸甘油酯，二山ate酸甘油酯和三山gly酸甘油酯以及泊洛沙姆的混合物。 还公开了用于减少与阿奇霉素给予哺乳动物有关的胃肠副作用的方法，包括向所述哺乳动物连续施用阿奇霉素和有效量的碱化剂，其中胃肠副作用的频率低于施用等剂量 进一步公开了在有需要的哺乳动物中治疗细菌或原生动物感染的方法，其包括向所述哺乳动物连续施用单剂量的口服剂型，其中所述口服剂型包含阿奇霉素和有效量 另外公开的是阿奇霉素多微粒，其包含阿奇霉素，表面活性剂; 和药学上可接受的载体。

    AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS
    9.
    发明申请
    AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS 审中-公开
    AZITHROMYCIN剂型减少副作用

    公开(公告)号：WO2005053650A8

    公开(公告)日：2005-12-01

    申请号：PCT/IB2004001654

    申请日：2004-05-14

    Applicant: PFIZER PROD INC ,  HAGEN TIMOTHY ARTHUR ,  HERBIG SCOTT MAX ,  LO JULIAN BELKNAP ,  THOMBRE AVINASH GOVIND ,  APPEL LEAH ELIZABETH ,  CREW MARSHALL DAVID ,  FRIESEN DWAYNE THOMAS ,  LYON DAVID KEITH ,  MCCRAY SCOTT BALDWIN ,  WEST JAMES BLAIR

    Inventor： HAGEN TIMOTHY ARTHUR ,  HERBIG SCOTT MAX ,  LO JULIAN BELKNAP ,  THOMBRE AVINASH GOVIND ,  APPEL LEAH ELIZABETH ,  CREW MARSHALL DAVID ,  FRIESEN DWAYNE THOMAS ,  LYON DAVID KEITH ,  MCCRAY SCOTT BALDWIN ,  WEST JAMES BLAIR

    IPC: C07H17/00 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/7052 ,  A61K47/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/44 ,  A61P31/04

    CPC classification number: A61K9/1611 ,  A61K9/143 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1694 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2031 ,  A61K31/7052

    Abstract: An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate,and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.

    Abstract translation: 包含阿奇霉素和有效量的碱化剂的口服剂型。 优选地，所述口服剂型包含有效量的碱化剂和阿奇霉素多颗粒，其中所述多颗粒包含阿奇霉素，单山嵛酸甘油酯，二苯乙酸甘油酯和枸橼酸甘油酯和泊洛沙姆的混合物。 通常，口服剂型包括任何合适的口服给药方式，例如用于口服悬浮液的粉末，单位剂量包或小药囊，片剂或胶囊。另外公开的是包含阿奇霉素，有效量的碱化剂和 一辆车。 优选地，阿奇霉素是多颗粒形式，其中所述多颗粒包括阿奇霉素，甘油单山嵛酸甘油酯，二苯甲酸甘油酯和枸橼酸甘油酯和泊洛沙姆的混合物。 还公开了一种减少与向哺乳动物施用阿奇霉素相关的胃肠道副作用的方法，包括向所述哺乳动物连续施用阿奇霉素和有效量的碱化剂，其中胃肠道副作用的频率低于施用相等剂量 的阿奇霉素。没有所述碱化剂的阿奇霉素的进一步公开是一种在有需要的哺乳动物中治疗细菌或原生动物感染的方法，其包括向所述哺乳动物连续施用单剂量的口服剂型，其中所述口服剂型包含阿奇霉素和有效量 的碱性试剂。另外公开了包含阿奇霉素，表面活性剂的阿奇霉素多颗粒; 和药学上可接受的载体。

Patent Agency Ranking